一分钟看懂
这是一项关于实体瘤的I 期研究，登记的药物或干预包括DC50292A，当前状态为招募中。登记地点显示中国福州、广州、南宁、哈尔滨等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
DC50292A · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fujian Cancer Hospital · 福州
- Sun Yat-Sen University Cancer Center · 广州
- Guangxi Medical University Cancer Hospital · 南宁
- Harbin Medical University Cancer Hospital · 哈尔滨
- Henan Cancer Hospital · 郑州
- Hunan Cancer Hospital · 长沙
- Shandong Cancer Hospital · 济南
- Sir Run Run Shaw Hospital · 杭州
公开的入选条件
- 1. Voluntarily signs the informed consent form, demonstrates understanding of the study, and is willing and able to comply with all trial procedures.
- 2. Age ≥18 years, regardless of gender.
- 3. Patients with histologically and/or cytologically confirmed solid tumors who are assessed by the investigator as having locally advanced, recurrent, or metastatic disease and have failed standard treatments at the current stage.
- 4. At least one measurable lesion as per RECIST v1.1 criteria, assessed via imaging (tumor lesions located in previously irradiated areas or those having undergone other local-regional therapies are generally not considered measurable unless clear progression
- 5. MTAP deficiency, defined by one of the following: willingness to provide sufficient archived tumor tissue or fresh biopsy samples for MTAP testing; or documentation of MTAP homozygous deletion via NGS/IHC or loss of MTAP protein expression in tissue; or ava
- 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- 7. Life expectancy ≥3 months.
- 8. Absence of severe hematological, hepatic, renal, coagulation, or cardiac dysfunction.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07071090；登记信息更新于 2026-09-16。